tiprankstipranks
Trending News
More News >

CuraTeQ Biologics Gains EMA Positive Opinion for Dazublys®

Story Highlights
CuraTeQ Biologics Gains EMA Positive Opinion for Dazublys®

Confident Investing Starts Here:

Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) just unveiled an update.

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its trastuzumab biosimilar, Dazublys®, intended for treating HER2-positive breast cancers. This endorsement marks an important step for Aurobindo Pharma in strengthening its biosimilars portfolio, with expectations for European Commission approval by July, furthering its commitment to launching at least ten biosimilars by 2030 to enhance cancer care and address unmet patient needs.

More about Aurobindo Pharma Ltd

Aurobindo Pharma Limited, through its subsidiary CuraTeQ Biologics, is a global biopharmaceutical company based in Hyderabad, India, focusing on developing biosimilars for cancer and autoimmune diseases. The company aims to provide high-quality, cost-effective therapies with a pipeline of fourteen biosimilars targeting immunology and oncology segments.

YTD Price Performance: -6.94%

Average Trading Volume: 34,176

Current Market Cap: 730.4B INR

For an in-depth examination of AUROPHARMA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1